Zhong Lun Advises on LianBio’s IPO on Nasdaq
Zhong Lun Advises on LianBio’s IPO on Nasdaq
On November 1, 2021, LianBio (Nasdaq: LIAN) announced its initial public offering and listing of American depositary shares on the Nasdaq Global Market. The total offering size will be US$ 325 million prior to the exercise of the over-allotment option. Goldman Sachs, Jefferies and BofA Securities acted as the joint book-running managers for this offering.
LianBio is a biotechnology company dedicated to bringing innovative therapeutic solutions to patients in Greater China and other major Asian markets. It was founded by Perceptive Advisors, a leading life sciences-focused investment firm. In accordance with relevant listing rules, LianBio filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for this offering.
Zhong Lun Law Firm acted as the PRC legal advisor for the issuer in this offering. The legal team from Zhong Lun was led by Anthony Zhao and William Jia and included Roy Zheng, Lindsay Zhang, Ruby Zheng, etc.
Professionals
-
-
-
Anthony ZHAO
Equity Partner
Shanghai
-
-
-
-
William JIA
Equity Partner
Shanghai
-